NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 02 July 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Alex Cale Present for items 1.1 to 5.2.2
4. Michael Chambers Present for all items
5. Dawn Cooper Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Pedro Saramago Goncalves Present for all items
11. John Hampson Present for all items
12. Louise Hunt Present for all items
13. Dr Steven Lloyd Present for items 1.1 to 5.1.3
14. Iain McGowan Present for all items
15. Stella O’Brien Present for all items
16. Dr Clare Offer Present for items 1.1 to 4.2.2
17. Amit Parekh Present for all items
18. Dr Arpit Srivastava Present for all items
19. Elizabeth Thurgar Present for all items
20. Dr Satish Venkateshan Present for items 1.1 to 4.2.2

NICE staff (key players) present

Jacoline Bouvy, Programme Director Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 1.1 to 4.2.2

Kate Moore, Project Manager Items 1.1 to 4.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Anna Willis, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5.1 to 5.2.2

Celia Mayers, Project Manager Items 5.1 to 6.2.2

Alex Filby, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Emily Crowe, Associate Director Items 6.1 to 6.2.2

Sally Doss, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Owen Swales, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Robert Wolff, KSR Items 1.1 to 4.1.3

Isaac Corro Ramos, KSR Items 1.1 to 4.1.3

Dan Gallacher, Warwick Evidence Items 5.1 to 5.1.3

Amin Mehrabin, Warwick Evidence Items 5.1 to 5.1.3

Vicky Wakefield, BMJ-TAG Items 6.1 to 6.1.3

Archie Walters, BMJ-TAG Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Andrew Clay, Patient expert, nominated by AMMF – The Cholangiocarcinoma Charity Items 1.1 to 4.1.3

Helen Morement, Patient expert, nominated by AMMF – The Cholangiocarcinoma Charity Items 4.1.3 to 4.1.3

Professor John Bridgewater, Professor of Medical Oncology - Clinical expert, nominated by Cholangiocarcinoma UK Items 1.1 to 4.1.3

Professor Peter Clark, CDF Lead, NHS England Items 1.1 to 4.2.1

Talha Munir, Consultant Haematologist – Clinical Expert

Nominated by Alexion Items 5.1 to 5.1.3

Morag Griffin, Consultant Haematologist – Clinical Expert

Nominated by PNH Service Items 5.1 to 5.1.3

Maria Piggin, Patient Expert Nominated by PNH Support UK Items 5.1 to 5.1.3

Karen Hasid, HEART UK Ambassador – patient expert, nominated by HEART UK Items 6.1 to 6.1.3

Adam Barratt, HEART UK Ambassador – patient expert, nominated by HEART UK Items 6.1 to 6.1.3

Jaimini Cegla, Consultant in Metabolic Medicine – clinical expert, nominated by HEART UK Items 6.1 to 6.1.3

Handrean Soran, Consultant Physician and Endocrinologist – clinical expert, nominated by HEART UK and Ultragenyx Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Prof. Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Prof. Andrew Renehan, Iftab Akram, Dr Kate Ren and Ugochi Nwulu.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 04 June 2024.

### Appraisal of Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Taiho Pharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11371/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Stella O’Brien, Satish Venkateshan, and Michael Chambers.
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. Closed session
  3. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     1. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11371)

### Appraisal of Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria [ID5088]

* 1. Part 1 – Open session
     1. The chair, Prof. Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Alexion Pharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10980/documents)
     3. The Chair led a discussion of the consultation comments presented to the committee.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10980)

### Appraisal of Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]

* 1. Part 1 – Open session
     1. The chair, Prof. Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from BMJ-TAG.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10655/documents)
     3. The chair led a discussion of the consultation comments presented to the committee.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10655)

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 06 August 2024 and will start promptly at 09:15am.